Completed PHASE4 INTERVENTIONAL NCT00203580

Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)

A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)

Sponsor: Canadian Institutes of Health Research (CIHR)

Conditions Thromboembolism Thrombosis Venous Thrombosis

Interventions Tinzaparin sodium

Updated 5 times since 2017 Last updated: Feb 8, 2007 Started: Dec 31, 1994 Completion: Mar 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Thromboembolism and Thrombosis and is currently completed. Canadian Institutes of Health Research (CIHR) leads this study, which shows 5 recorded versions since 1994 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Canadian Institutes of Health Research (CIHR)
Dupont Applied Biosciences
LEO Pharma
University of Calgary

Data source: University of Calgary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Calgary, Canada